학술논문

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial
Document Type
Article
Source
In: Journal for ImmunoTherapy of Cancer. (Journal for ImmunoTherapy of Cancer, 13 March 2024, 12(3))
Subject
Language
English
ISSN
20511426